{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:28:27Z","timestamp":1793726907220,"version":"4.6.1"},"reference-count":10,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>During PREVENT (a phase 3, randomized, double-blind, placebo-controlled, time-to-event study) and its open-label extension (interim analysis), 33 adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD) received eculizumab monotherapy for a median of 2.8 years (range, 14 weeks\u20135.2 years). At 192 weeks (~4 years), 96% of these patients were free from adjudicated relapses (Kaplan\u2013Meier analysis; 95% confidence interval, 75.7\u201399.4). During PREVENT, 95% (20\/21) of patients receiving eculizumab monotherapy had no disability worsening. Eculizumab monotherapy provides effective long-term relapse prevention, relieving the chronic immunosuppression burden in patients with AQP4-IgG + NMOSD. ClinicalTrials.gov; PREVENT: NCT01892345; open-label extension: NCT02003144.<\/jats:p>","DOI":"10.1177\/13524585211038291","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T07:05:54Z","timestamp":1631171154000},"page":"480-486","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":79,"title":["Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension"],"prefix":"10.1177","volume":"28","author":[{"given":"Sean J","family":"Pittock","sequence":"first","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan\/Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, Fukushima City, Japan\/Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Berthele","sequence":"additional","affiliation":[{"name":"Department of Neurology, School of Medicine, Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-8419","authenticated-orcid":false,"given":"Ho Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology, Research Institute and Hospital, National Cancer Center, Goyang, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9221-5716","authenticated-orcid":false,"given":"Celia","family":"Oreja-Guevara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Clinico Universitario San Carlos, Madrid, Spain\/Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain\/IdISSC, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-8948","authenticated-orcid":false,"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan\/Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7969-8346","authenticated-orcid":false,"given":"Michael","family":"Levy","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University, Baltimore, MD, USA\/Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulian","family":"Shang","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Yountz","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Miller","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00f3is\u00edn","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals, Boston, MA, USA\/Rallybio, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean M","family":"Wingerchuk","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the PREVENT Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"bibr1-13524585211038291","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70216-8"},{"key":"bibr2-13524585211038291","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01297-w"},{"key":"bibr3-13524585211038291","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866"},{"key":"bibr4-13524585211038291","unstructured":"Soliris US Prescribing Information. SOLIRIS\u00ae (eculizumab) [US Prescribing Information], 27 June 2019. Alexion Pharmaceuticals, Inc. USA, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125166s431lbl.pdf (accessed 20 November 2019)."},{"key":"bibr5-13524585211038291","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26447"},{"key":"bibr6-13524585211038291","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12347"},{"key":"bibr7-13524585211038291","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.423"},{"key":"bibr8-13524585211038291","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15790"},{"key":"bibr9-13524585211038291","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"bibr10-13524585211038291","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585211038291","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585211038291","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585211038291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:07:25Z","timestamp":1777694845000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585211038291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1177\/13524585211038291"],"URL":"https:\/\/doi.org\/10.1177\/13524585211038291","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]}}}